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Abstract
Background: The time from a referral for suspected lung cancer is received at a hospital until treatment start has
been defined as a quality indicator. Current Norwegian recommendation is that ≥70% should start surgery or
radiotherapy within 42 calendar days and systemic therapy within 35 days. However, delays can occur due to
medical complexity. The aim of this study was to quantify the proportion of patients who started treatment within
the recommended timeframes; and to assess the proportion of non-complex patients for which there were no
good reasons for delays.
Methods: We performed a retrospective chart review of all patients diagnosed with lung cancer at a university
hospital during 2011–2013. We defined “non-complex” patients as those who underwent ≤1 tissue diagnostic
procedure and had no delays due to comorbidity, intercurrent disease or complications to diagnostic procedures
(“Medical delays”) of more than three days.
Results: Four hundred forty-nine cases were analyzed; 142 (32%) had >1 tissue diagnostic procedures; 67 (15%) had
medical delays >3 days; 262 (58%) were non-complex and 363 (81%) received treatment for lung cancer. Median number
of days until surgery or radiotherapy was 48 (overall) and 41 (non-complex patients). The proportions who started surgery
or radiotherapy within 42 days were 41% (overall) and 56% (non-complex). Corresponding numbers for systemic therapy
were 29 days (overall) and 25 days (non-complex), and 64% (overall) and 80% (non-complex).
Conclusion: Fewer lung cancer patients than desired started treatment within the recommended timeframes.
Even among the least complex patients, too few patients received timely treatment. The reasons need to be
identified and understood, and changes in the organization appear to be necessary in order to offer timely
treatment to more patients.
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Background
Waiting while undergoing investigations for suspected
cancer is distressing for patients and their families [1–3],
and waiting for cancer treatment to start is perceived as
a medical risk that may affect treatment outcomes [4, 5].
It is not clear that shorter time to treatment influences
survival [6–9], but there is fair evidence that prompt
management improves patient satisfaction and reduces
anxiety [1, 2, 10–12]. Thus, efficient organization of
cancer diagnosis and treatment is a public and political
goal. Political strategies to improve organization include
development of indicators and standards for timely diag-
nosis and treatment.
The British Thoracic Society and the Danish Lung
Cancer Group presented the first specifications for
timely lung cancer diagnosis and treatment in 1998
[8, 13]. In June 2011, the first Norwegian recommenda-
tions regarding timelines for diagnosis and treatment of
cancer were presented. At that time, at least 80% of all
cancer patients were to start treatment within 20
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working days from a referral letter for suspected cancer
was received at a hospital. National guidelines for cancer
care organization were developed, and the National
Standard for lung cancer diagnosis and treatment was
presented on January 1, 2015 [14]. For suspected lung
cancer, the first hospital appointment should be offered
within seven calendar days of receiving a referral letter; a
treatment decision should be made within 28 calendar
days; systemic therapy should start within 35 calendar
days, and surgery or radiotherapy within 42 calendar days.
The overall aim is that more than 70% of lung cancer pa-
tients start treatment within these timeframes [15].
The metrics for timely lung cancer care vary between
health care organizations [16–18], but all accept that
good reasons for delay exist and tolerate longer time-
frames for a specified proportion of patients. Diagnostic
workup for lung cancer may be complex and it is not
clear whether it is realistic or medically correct that all
patients start treatment within 35 or 42 days. Tissue
sampling may be difficult; the number of lesions that
should be punctured varies; and complications to diag-
nostic procedures occur. Many patients are elderly and
suffer from co-existing conditions. Thus, intercurrent
diseases are common, and some patients want breaks
between the diagnostic procedures or before starting
treatment [19]. Most studies do not consider these fac-
tors, since they are based on registry data. Thus, there is
no established method for assessing complexity in diag-
nostic work-up for lung cancer [20].
Aims of the study
The main aims of the study were to investigate how
many patients at a university hospital who started
treatment for lung cancer within the timeframes recom-
mended in Norway; and to quantify the proportion of
patients who had delays due to complex diagnostic
workup, intercurrent disease or patients’ wish.
Methods
Study setting
The Norwegian health care is mainly public, and the na-
tional health insurance system cover expenses exceeding
€ 233 per year [21]. Approximately 700 000 people live
in Central Norway. There are seven hospitals in the
region. All hospitals diagnose lung cancer and offer
systemic therapy. Radiotherapy is offered at two sites.
Complex cases are referred to St. Olavs Hospital, which
is the university hospital in the region, but also serves as
the primary hospital for 380 000 inhabitants. Most pa-
tients within the primary catch-up area lives within
30 min from the hospital. St. Olavs Hospital has all
facilities for diagnostic workup for lung cancer including
the only PET CT (Positron Emission Tomography Com-
puter Tomography) scanner in the region (since October
2013), and all lung cancer surgery is performed here.
PET CT was performed outside our health region during
most of the study period (until October 2013). From
2009 to 2013, the annual world standardized lung- and
tracheal cancer rate in Norway was 34.9 in men and 26.0
in women [22]. The annual incidence in the primary
catchment area of St. Olavs Hospital was similar to the
incidence in all of Norway.
The Department of Thoracic Medicine is responsible
of lung cancer diagnosis and they offer systemic therapy.
The Cancer Department provide radiotherapy, and sur-
gery takes place in the Department of Cardio-Thoracic
Surgery. Diagnostic workup for lung cancer is mainly
done on an outpatient basis. A weekly, regional, multi-
disciplinary tumor board meeting is held between
pulmonary physicians, thoracic surgeons, an oncologist
specializing in lung cancer (Norwegian oncologists are
trained in both medical oncology and radiotherapy), a
thoracic radiologist, a specialist in nuclear medicine, a
pathologist and a nurse coordinator. Between September
1, 2012 and January 31, 2013, the multidisciplinary team
revised the routines and procedures for lung cancer
diagnosis and a standardized care pathway was devel-
oped that included the national recommendations for
timeliness. The pathway did not include protocols that
could limit timeliness. They also assigned a pulmonary
phycician specializing in diagnosis, staging and treat-
ment of lung cancer as the leader of the multidisciplin-
ary team.
Study design
The study is a retrospective analysis of all cases that
started diagnostic work-up and were diagnosed with
lung cancer from January 1, 2011 to December 31,
2013, at the Department of Thoracic Medicine at St.
Olavs Hospital – Trondheim University Hospital,
Trondheim, Norway.
Case selection and data collection
Patients registered with ICD 10 codes C34.0-9 (“lung
cancer”) were identified from the hospital patient admin-
istrative system. Patient data were collected from the
hospital electronic medical records.
Stage of disease was assessed according to the 7th
edition of the TNM classification of lung cancer [23].
Patients were classified as having non-small-cell lung
cancer (NSCLC); small-cell lung cancer (SCLC); other
primary lung cancers; or no tissue diagnosis. Treatment
was classified as curative treatment (surgery, radical
radiotherapy or radio-chemotherapy of stage I-III dis-
ease); palliative treatment; or no cancer treatment/death
before start of treatment. First treatment was either sur-
gery or radiotherapy, or systemic therapy (including
when chemotherapy was administered concurrently with
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radiotherapy). Patients were classified as “hospitalized”
when admitted to the hospital due to the patient’s condi-
tion at start of diagnostic work-up, otherwise they were
classified as “outpatient”.
Complexity
In our experience, the factors that influence the time-
lines the most are the number of tissue diagnostic
procedures required [24–27], and delays for medical
reasons [27, 28].
Tissue diagnostic procedures are performed to diagnose
lung cancer; to do molecular and histopathological classifi-
cation; and to assess extent of disease. These procedures
include bronchoscopy; endobronchial ultrasound-guided
trans-bronchial needle aspiration (EBUS TBNA); trans-
thoracic needle biopsy; or others. Delays in diagnostic
workup for medical reasons were categorized as
hospitalization caused by complications to a diagnostic
procedure; synchronous investigation for other cancer;
synchronous treatment of other cancer; treatment of co-
morbidity; or intercurrent disease.
We defined “non-complex patients” as having under-
gone ≤1 tissue diagnostic procedure and having no
medical delays of >3 days. “complex patients” were sub-
classified as having >1 tissue diagnostic procedures and
no medical delays of >3 days; ≤1 tissue diagnostic
procedure and medical delays of >3 days; or >1 tissue
diagnostic procedures and medical delays of >3 days.
Intervals
We defined start time as the date when a referral letter
for suspected lung cancer was received by the Depart-
ment of Thoracic Medicine – or the date when the deci-
sion was made to start diagnostic workup in patients
with a known single pulmonary nodule (SPN). We de-
fined the time for treatment decision as the date when
such a decision was documented in the EMR. We de-
fined start of treatment as date of surgery, first fraction
of radiotherapy, first day of intra-venous chemotherapy,
or date of prescription of oral cancer therapy. Time to
treatment treatment was defined as the number of cal-
endar days from start time until start of treatment.
According to Norwegian recommendations, start of
treatment within 42 days (surgery or radiotherapy) or
35 days (systemic therapy) was considered “timely
treatment” [14].
Statistical analyses
We used chi-square test for univariate analysis. Factors
influencing the likelihood of timely treatment (patient
and disease characteristics as well as PET CT – since
PET CT was not available at St. Olavs Hospital during
most of the study period) were explored using logistic
regression analysis. We used the Stata/IC 13.1 package
for Windows for the statistical analyses, and considered
a p-value of < 0.05 to be statistically significant.
Results
Case selection and baseline characteristics
Nine hundred ninety patients were identified with “lung
cancer” for the first time in the hospital registry in the
study period. Four hundred three started diagnostic
workup in other hospitals (n = 333) or other depart-
ments at St. Olavs Hospital (n = 34); 66 were diagnosed
before January 1, 2011; 103 patients did not have lung
cancer, and five patients declined to participate in the
study. Thus, 449 patients were analyzed. St. Olavs
Hospital was the primary hospital for 436 (97%) of these.
The proportion at an age ≥70 was higher in 2013
(67%) than in 2011 (52%) and 2012 (57%) (p = 0.04) due
to a variation in the proportions <70 and 70–74. The
proportion aged 75 or higher was stable. The proportion
who underwent PET CT increased from 10% in 2011,
36% in 2012 to 51% in 2013 (p < 0.0001). Otherwise,
there were no significant variations in baseline charac-
teristics or treatment between 2011, 2012 and 2013. 42%
received curative treatment, 39% palliative, and 18% re-
ceived no cancer treatment. Seven patients (1.6%) died
before a treatment started (Table 1).
Complexity
Forty-nine (11%) of patients underwent no tissue
diagnostic procedure, 258 (57%) had one, 100 (22%)
had two, and 42 (9%) had more than two procedures.
Five hundred and ninety-five procedures were per-
formed (279 bronchoscopies, 150 EBUS-TBNA, 166
other procedures).
Sixty-seven patients (15%) had a medical delay: 11 due
to synchronous cancer, 8 had acute cardiovascular
disease, 11 lung or bronchial infection, 23 poor lung- or
general condition, 5 fracture or trauma, and 9 other con-
ditions. There were delays ≥1 week due to patients’ per-
sonal preferences or no show in 13 (3%). Among these,
eight had >1 tissue diagnostic procedure and/or medical
delay of >3 days.
Two hundred and sixty-two patients (58%) were
classified as non-complex, and there was no signifi-
cant variation between years (2011: 56%, 2012: 55%,
2013: 63%; p = 0.37). Among complex patients, 120
(64%) had >1 tissue diagnostic procedure, 45 (24%)
had medical delay of >3 days, and 22 (12%) had both >1
tissue diagnostic procedure and medical delay of >3 days.
The proportion of complex among patients with NSCLC/
other primary lung cancers was 49% (n = 156); SCLC, 25%
(n = 16); no tissue diagnosis, 24% (n = 15) (p < 0.0001).
Among patients who received treatment the proportion of
complex was 44% (n = 161); no treatment, 30% (n = 26)
(p = 0.02). There was no significant difference in the
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proportios who were complex in patients who had a
PET CT (46%, n = 67) compared to those who did not
have a PET CT (40%, n = 120) (p = 0.21) (Table 1).
The proportion with more than one tissue diagnostic
procedure was higher among those who received treat-
ment (33% in curative and 36% in palliative treatment),
than among those who did not receive cancer treatment
or died before treatment started (19%) (p = 0.01); while
the proportions with medical delay were similar (cura-
tive treatment, 19%; palliative treatment, 12%; no treat-
ment or death before treatment, 13% (p = 0.12)) (Fig. 1).
There were no significant differences in the numbers
who had >1 tissue procedure depending on stage of
disease (stage I: 34 (30%); stage II: 16 (38%); stage III: 38
(33%); stage IV: 54 (30%) (p = 0.77). The proportion of
medical delays of >3 days was highest for stage II pa-
tients (stage I: 21 (19%); stage II: 12 (29%); stage III: 17
(15%); stage IV: 17 (10%) (p = 0.009)).
PET CT was performed in 20 (11%) of stage IV pa-
tients, and 126 (47%) of stage I-III patients (p < 0.0001),
and the proportion was consequently higher among
those receiving curative treatment (113, 59%) than those
offered palliative treatment (28, 16%) or no treatment/
death before treatment (5, 6%) (p < 0.0001).
Intervals
Median time to treatment decision was 26 days (range:
0–283), and 247 (56%) had a decision within 28 days.
Among patients who did not receive any cancer treat-
ment, median time to that decision was 18 days (range:
0–100), and was reached in ≤28 days in 78%.
In the overall population, median time to start of treat-
ment was 42 days (range: 2–296), and 179 (49%) re-
ceived timely treatment. The proportion who received
timely treatment was lowest among those eligible for
surgery or curative radiotherapy (Fig. 2). More patients
received timely treatment among non-complex (133,
66%) than complex patients (46, 29%) (p < 0.0001);
among those offered palliative treatment (113, 65%) than
patients receiving curative treatment (66, 35%) (p < 0.0001);
Table 1 Baseline characteristics
Variables Total 2011 2012 2013 Non-complex patientsa Complex patientsb
N = 469 n = 147 n = 146 n = 156 n = 262 n = 187
Age, median (range) 72 (40–93) 70 (40–90) 71 (46–91) 73 (54–93) 72 (46–93) 72 (40–89)
Age≥ 70 years, n (%) 265 (59%) 77 (52%) 84 (57%) 104 (67%) 155 (59%) 110 (59%)
Women 206 (46%) 62 (42%) 76 (52%) 68 (44%) 125 (48%) 81 (43%)
TNM stage
I 112 (25%) 29 (20%) 39 (27%) 44 (28%) 65 (25%) 47 (25%)
II 42 (9%) 19 (13%) 10 (7%) 13 (8%) 18 (7%) 24 (13%)
III 116 (26%) 43 (29%) 34 (23%) 39 (25%) 68 (26%) 48 (26%)
IV 179 (40%) 56 (38%) 63 (43%) 60 (38%) 111 (42%) 68 (36%)
Histology
NSCLC 312 (69%) 105 (71%) 110 (75%) 97 (62%) 161 (61%) 151 (81%)
SCLC 65 (14%) 18 (12%) 19 (13%) 28 (18%) 49 (19%) 16 (9%)
Other primary lung cancers 9 (2%) 2 (1%) 1 (1%) 6 (4%) 4 (2%) 5 (3%)
No tissue diagnosis 63 (14%) 22 (15%) 17 (11%) 25 (16%) 48 (18%) 15 (8%)
Treatment
Surgery 116 (26%) 37 (25%) 39 (27%) 40 (26%) 59 (23%) 57 (30%)
Curative radiotherapyc 74 (16%) 18 (12%) 22 (15%) 34 (22%) 46 (18%) 28 (15%)
Palliative radiotherapy 48 (11%) 19 (13%) 15 (10%) 14 (9%) 26 (10%) 22 (12%)
Palliative systemic therapy 120 (27%) 38 (26%) 43 (29%) 39 (25%) 69 (26%) 51 (27%)
Palliative surgery 5 (1%) 1 (1%) 1 (1%) 3 (2%) 2 (1%) 3 (2%)
No cancer treatment 79 (18%) 31 (21%) 24 (16%) 24 (15%) 55 (21%) 24 (13%)
Death before treatment 7 (2%) 3 (2%) 2 (1%) 2 (1%) 5 (2%) 2 (1%)
Out-patient investigation 290 (65%) 93 (63%) 98 (67%) 99 (63%) 163 (62%) 127 (68%)
PET CT 146 (33%) 15 (10%) 52 (36%) 79 (51%) 79 (30%) 67 (36%)
aNon-complex, ≤1 tissue diagnostic procedure and no medical delays of >3 days
bComplex, >1 tissue diagnostic procedures and/or medical delay of >3 days
cCurative radiotherapy includes concurrent radio-chemotherapy and radiotherapy alone
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and among those who did not have a PET CT (137, 62%)
than patients who underwent PET CT (42, 30%) (p <
0.0001) (Fig. 3).
The proportions who received timely treatment did
not vary significantly from 2011 until 2013 in the
overall population, but the proportion of non-
complex patients that started surgery or radiotherapy
within 42 days decreased from 2011 (n = 27, 75%),
until 2012 (n = 16, 47%), and 2013 (n = 25, 49%) (p =
0.03) (Fig. 4).
Median number of days until surgery or radiotherapy
was 48 days (range: 5–296) among all patients (non-
complex: 41 days (range: 5–145), complex: 59 days
(range: 11–296)). Surgery or radiotherapy started within
42 days in 93 (41%) of all patients (non-complex: 68
(56%), complex: 25 (23%)).
Fig. 1 Proportions of patients with >1 tissue diagnostic procedure and medical delay >3 days. Distribution in the overall population, and split for
treatment intention. Complex patients were defined as having >1 tissue diagnostic procedure and/or medical delay of >3 days.
Fig. 2 Timeliness for different treatments, split for complexity. Calendar days from the when the hospital received the referral letter for suspected
lung cancer until the different treatments started. Non-complex patients were defined as having ≤1 tissue diagnostic procedure and no medical
delay of >3 days, complex patients as having >1 tissue diagnostic procedure and/or medical delay of >3 days. The reference lines refer to the
Norwegian recommendations for timely lung cancer treatment, which are 42 days for surgery and radiotherapy, and 35 days for systemic therapy
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Overall, 43 (37%) underwent surgery within 42 days
(non-complex: 33 (56%), complex: 10 (18%); p < 0-0001).
Corresponding numbers for curative radiotherapy was
12 (20%) (non-complex: 10 (29%), complex 2 (8%); p =
0.04); and for palliative radiotherapy 33 (69%) (non-com-
plex: 23 (88%), complex: 10 (45%); p = 0.001) (Fig. 2).
Median number of days until systemic therapy was
29 days (range: 2–201) among all patients (non-com-
plex: 25 days (range: 2–58), complex: 43 days (range:
5–201)). Systemic treatment started within 35 days
in 86 (64%) of all patients (non-complex: 65 (80%),
complex: 21 (39%)). Among those 15 patients with
limited disease small-cell lung cancer who received
curative chemo-radiotherapy, 12 (80%) were non-
complex, and 11 (73%) received timely systemic
treatment (thoracic radiotherapy was administered
concurrrent with the second chemotherapy-course).
Palliative systemic therapy was administered timely
in 75 (63%) (non-complex: 56 (81%), complex: 19
(37%); p < 0.0001) (Fig. 2).
Fig. 3 Proportions that received timely lung cancer treatment. Distributions of timely and not timely treatment in non-complex versus complex,
curative versus palliative treatment, and having a PET CT versus no PET CT
Fig. 4 Time to treatment split for year. Calendar days from the when the hospital received the referral letter for suspected lung cancer until start
of treatment. Non-complex patients were defined as having ≤1 tissue diagnostic procedure and no medical delay of >3 days, complex patients
as having >1 tissue diagnostic procedure and/or medical delay of >3 days. The reference lines refer to the Norwegian recommendations for
timely lung cancer treatment, which are 42 days for surgery and radiotherapy, and 35 days for systemic therapy
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Associations of complexity with timely treatment
Multivariate logistic regression analysis adjusted for pa-
tient characteristics (age <70/≥70, sex, outpatient/hospi-
talized), year and tumor characteristics (tissue diagnosis,
stage) showed that complex patients were in significant
risk of not timely treatment (OR, 0.16; 95% CI, 0.09-
0.27). The increased risk remained significant when we
adjusted for treatment intention, and whether the pa-
tient underwent PET CT or not (OR, 0.15; 95% CI,
0.09–0.26). There was no significant difference in the
risk of not timely treatment between patients receiving
palliative (reference category) and curative treatment
(OR, 0.80; 95% CI, 0.37-1.68); while undergoing PET CT
was a significant risk factor (OR, 0.32; 95% CI, 0.17-
0.61). There was also no significant difference between
patients with NSCLC/other primary lung cancers (refer-
ence category), SCLC (OR, 1.05; 95% CI, 0.49-2.28), and
no tissue diagnosis (OR, 0.35; 95% CI, 0.12-1.04). The
risk of not timely treatment was lower in stage IV than
stage I-III patients (OR, 2.72; 95% CI, 1.22-6.06); and
lower in hospitalized patiens than outpatients (OR, 2.35;
95% CI, 1.28-4.31).
Discussion
In this cohort of 449 patients diagnosed with lung can-
cer at a regional cancer center, we found that time to
start of treatment exceeded the Norwegian recommen-
dations in 51% of those 363 that started treatment.
Overall, timely treatment started in 41% of those who
underwent surgery or received radiotherapy, whereas
systemic therapy started within the recommended time-
frame in 64%. Among the least complex patients, the
timeframes where met for those who were offered sys-
temic therapy, but not for those who underwent surgery
or radiotherapy.
Interestingly, the proportion who was offered timely
sugery or radiotherapy decreased from 2011 until 2013.
The reason appears to be significant increase in the use
of PET CT for staging of these patients due to changes
in guidelines and increasing capacity in Norway. The
average time for PET CT was 20 days, and in the multi-
variate analysis, PET CT was significantly associated
with longer timeframes than recommended.
Time to treatment is a commonly used indicator of
health care efficiency, but the timeframes vary in differ-
ent studies and guidelines [16–18, 29]. Most commonly
used are the intervals from “day of first abnormal chest
image” [9, 30, 31], or “day a referral letter for suspected
lung cancer was received” [6] until admission for
surgery, the date of surgery, the first fraction of radio-
therapy or first day of systemic therapy.
The Danish guidelines recommend that time from re-
ceiving a referral letter for suspected lung cancer until
start of treatment should be ≤42 days in ≥85% of cases.
In a publication from 2013 [32], they reported that the
proportions of patients that started treatment within this
timeframe were 63.2% (n = 714) for surgery, 73.5%
(n = 687) for radiotherapy and 78.4% (n = 1660) for
chemotherapy. The key indicator defined by the
Swedish Lung Cancer Study Group is the interval
from a referral letter for suspected lung cancer is re-
ceived until a treatment decision is made. The goal
is that a decision is made within 28 days in ≥80% of
patients. In 2012–14, the goal was met in 47% (N =
10,369) [33], while a treatment decision was made
within 28 days for 56% of our patients. The National
Health Services (NHS) England recommends that
patients start treatment within 62 days following an
urgent general practitioner (GP) referral in ≥85% of
patients. In 2013–14, 78.5% (N = 12,075) started
treatmentwithin this timeframe [34], while 75%
started treatment within 60 days in our cohort. We
have not found any documentation of the rationale
for the definition of the Norwegian timeframes,
though they appear to be quite similar to the Danish –
which are based on observations [17].
The results are not necessarily comparable due to
varying lung cancer incidence [35], and there are
probably differences in the organization of the health
care services and availability of PET CT. Still, it appears
that the situation at our hospital is similar to what was
observed in Sweden and England, whereas time to sur-
gery and radiotherapy is longer at our center than in
Denmark.
The mean number of tissue diagnostic procedures was
higher in Denmark [36] (1.66 vs. 1.33 in our cohort) -
which might explain the higher proportion of patients
with confirmed tissue diagnosis (94% vs. 86% in our co-
hort). The use of PET CT was much lower in our cohort
(33%) than in Denmark (62%) [36]. The proportion of
patients who received lung cancer treatment (81%) was
higher than in Denmark (74%) [36] and England and
Wales (60%) [37]. We cannot offer any obvious explan-
ation since the study was not designed to investigate this
aspect. Possible reasons include that lung cancer patients
are treated in our public health care system that provides
equal care for all inhabitants, and that a large proportion
of patients in our area live close to the hospital.
No national guidelines recommend that all patients
start treatment within the specified timeframe. Thus, it
appears to be accepted that the diagnostic workup takes
more time in some cases. We are, however, not aware of
any studies aiming at quantifying the number of patients
that should start treatment within the given timeframes.
Some studies have shown that treatment is delayed if a pa-
tient has comorbidity [28, 38], or an adequate tissue sam-
ple is not obtained at first attempt [24, 25], —supporting
our definition of “complex patients”. Our definition is
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further supported by the large difference in proportions
who started timely treatment between non-complex and
complex patients. We consider our defintion to be conser-
vative. In our opinion, the health care services are not op-
timally organized if it takes more than 35 or 42 days to
start treatment if only one tissue diagnostic procedure is
required to complete diagnostic workup and there are no
delays for medical reasons. One might argue that it should
be possible to conduct at least two tissue procedures
within the recommended timeframes. In our cohort, the
results do not change much if such a cut-off value is ap-
plied – the proportion of non-complex patients receiving
timely treatment changes from 66 to 58%. We have, how-
ever, chosen to use the cut-off of one tissue procedure
since we presume that it is difficult to argue that this rep-
resents a non-complex patient.
The proportion of non-complex was higher among
those who did not receive any lung cancer treatment.
This has to be interpreted with caution. Many of these
patients did not undergo an appropriate diagnostic
workup since many were considered ineligible for treat-
ment due to poor performance status or significant co-
morbidity, or, in some cases, because the patients did
not want a complete workup.
The main limitation of our study is the retrospective
design, which prohibited a uniform and systematic as-
sessment of medical delays and delays caused by the pa-
tients’ preferences or no show. Furthermore, this is a
single institution study, and not population-based. On
the other hand, we are not aware of any other studies of
timeliness in diagnostic workup and start of treatment
for lung cancer that have assessed diagnostic complexity
and medical delays. Our data are based on studies of in-
dividual medical records and not registry-based. The
population represents consecutive patients diagnosed
and treated at a single institution, and the patient char-
acteristics are similar as in other unselected lung cancer
polpulations [39].
Overall, the time to treatment was much longer than
recommended in our cohort, − even among non-
complex patients. Possible explanations include subopti-
mal organization, failure to comply with guidelines for
diagnostic workup, low capacity for key procedures and
a general lack of resources. It goes beyond the scope of
this first sub-study of our project to perform value
stream analyses, but we have collected these data which
will be analyzed to better understand how delays can be
avoided. The results will be presented in a separate art-
icle. Thus, we have currently not evaluated whether the
recommended timeframes are feasible or realistic in this
first sub-study of our project, but the results might pro-
vide valuable information about the proportion of pa-
tients who should receive timely lung cancer treatment.
Considering that 56% of patients who started treatment
were non-complex, using a conservative definition of
complexity, the goal of timely treatment in 70% of cases
does not appear to be unrealistic.
Conclusion
49% of all lung cancer patients diagnosed at a university
hospital started treatment within the official Norwegian
timeframes. Among the least complex lung cancer pa-
tients, only 66% of patients received timely treatment.
The reasons for delays needs to be identified and
organization needs to be improved in order to meet the
recommended timeframes.
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